GENCLIS SA

📍 Vandoeuvre-lès-Nancy, France🗓 Founded 2004👥 5 employees💰 Last funded 2004
Biotechnology Research🌐 GENCLIS.COM
Website LinkedIn
GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in GENCLIS SA?
GENCLIS SA has 1 investor on record on gritt.io, including 1 early-stage backers.
When did GENCLIS SA last raise funding?
The most recent investment in GENCLIS SA recorded on gritt.io was in 2004.
When was GENCLIS SA founded?
GENCLIS SA was founded in 2004.
What industry is GENCLIS SA in?
GENCLIS SA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GENCLIS SA based?
GENCLIS SA is headquartered in Vandoeuvre-lès-Nancy, France.